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  The first human bone marrow transplantation in a patient 
with hematologic malignancy took place in the 1950s, but 
only transient engraftment of the bone marrow was noted 
[1]. In the 1960s, additional information regarding the HLA 
system became available; the serologic HLA typing method 
was developed; and bone marrow transplantations for chil-
dren with immnunodeficiency were successfully performed 
[2]. Hematopoietic stem cell transplantation (HSCT) has 
now become an established and potentially curative treat-
ment modality for many malignant and nonmalignant dis-
eases affecting the hematopoietic and immune systems. 
However, only approximately 30% of the patients requiring 
HSCT have an HLA-matched sibling donor; the remaining 
70% need to find alternative sources of hematopoietic stem 
cells (HSCs), such as an HLA-mismatched related donor, 
a closely HLA-matched unrelated donor (URD), or umbilical 
cord blood. 
  The alloantigens differing between donors and recipients 
become targets for T-cell recognition. Hence, large numbers 
of genetic differences between donors and recipients in-
crease the risk of both graft rejection and graft-versus-host 
disease (GVHD); the graft-versus-tumor effect may be 
beneficial. Therefore, the most important determinant of 
successful allogeneic HSCT is the degree of HLA matching 
between the donor and recipient. HLAs are alloantigens 
and cell surface molecules encoded by class I (HLA-A, 
HLA-B, and HLA-C) and class II (HLA-DR, HLA-DP, and 
HLA-DQ) genes, which are a series of closely linked loci 
known as the major histocompatibility complex (MHC) that 
are located on chromosome 6 (6p21.3) in humans [3]. 
  Historically, HLA typing was conducted by serologic test-
ing by using antiserum in complement-dependent cytotoxic 
assays. Recently, more precise DNA-based HLA typing 
methods using molecular techniques, such as sequence- 
specific oligonucleotide probe hybridization, sequence- 
specific primer amplification, sequencing-based typing, and 
reference strand-based conformation analysis, have been 
developed and are frequently used. HLA are highly poly-
morphic, and gene sequencing analysis has revealed more 
than 800 HLA alleles. The current standard is HLA typing 
at the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 
genetic loci. An HSCT donor is referred to as a “10/10 
allele match” or “perfect match” when both HLA alleles 
are identical at each of the HLA-A, HLA-B, HLA-C, 
HLA-DRB1, and HLA-DQB1 loci. While searching for an 
unrelated donor, high-resolution (4-digit) genetic typing 
of both the patient and the donor is necessary [4, 5].
  In cases of perfect match, minor histocompatibility anti-
gens, which are naturally processed peptides derived from 
normal cellular proteins, may evoke a strong MHC-re-
stricted response because of the presence of different poly-
morphisms in the donor and in the recipient. Natural killer 
(NK) cells may also contribute to alloreactivity, particularly 
in haploidentical HSCT, through an interaction between 
killer immunoglobulin-like receptors (KIRs) on NK cells 
and HLA class I alleles (particularly HLA-C) on mismatched 
cells [3].
　Many retrospective studies have been done to analyze 
the effects of HLA mismatches (Mms) in adult patients who 
had undergone URD HSCT in different countries [5-8]. 
Crocchiolo et al. [6] reported that Mms patients with 9/10 
allele match showed a significantly higher risk of mortality, 
graft failure, and acute GVHD (aGVHD) than patients with 
10/10 allele match. Hauzenberger et al. [5] showed that 
patients with HLA class I allele Mms had high risk of aGVHD 
and transplant-related mortality (TRM), but HLA class II 
allele Mms were associated with improved survival. 
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rates in URD HSCT patients at any matching level, and 
did not observe augmented graft-versus-leukemia (GVL) 
effects in Mm URD HSCT patients. However, Kawase et 
al. [8] reported that, particularly in CML patients, donor-re-
cipient pairs with combinations of HLA-DPB1 were asso-
ciated with a significantly reduced risk of relapse and better 
overall survival than completely matched donor-recipient 
pairs because of the GVL effects.
　In this issue of the Korean Journal of Hematology, Park 
et al. [9] report the impact of HLA matching on the outcome 
of URD HSCT in Korean children. This was the first large, 
multicenter study to define the relationship between HLA 
typing and disease outcomes in Korean children who had 
undergone URD HSCT. Park et al. retrospectively analyzed 
a large group of patients (N=142, including 109 patients 
with hematologic malignancies and 33 patients with 
non-malignant diseases; all the patients belonged to the 
pediatric age group [≤18 years old]) who had undergone 
URD HSCT, and all HSC donors and patients were fully 
typed for HLA-A, HLA-B, HLA-C, and HLA-DR by using 
high-resolution molecular typing (4-digit level). Park et al. 
suggested that increased numbers of HLA Mms were asso-
ciated with reduced overall survival, increased risk of grade 
III-IV aGVHD, and greater TRM risk, thus confirming the 
results of many other studies [5-7]. Other important ob-
servations included that a single locus Mm at HLA-B or 
HLA-C was associated with significantly lower survival 
compared to the survival of patients with 8/8 allele match 
or a single Mm at HLA-A or DR; these results vary in 
American and Japanese reports. A single locus Mm at HLA-A 
showed significant association with high risk of grade III-IV 
aGVHD, and a single locus Mm at HLA-B showed significant 
association with high risk of TRM [9]. In their study, Park 
et al. clearly showed that the disparity in HLA class I, 
regardless of antigen or allele Mm, had significant negative 
impacts on the outcome of URD HSCT and was associated 
with poor survival and high risk of GVHD and TRM. Their 
study also provided useful information regarding the impact 
of a specific single HLA locus Mm on disease outcomes 
in Korean children. This information will be important 
while choosing optimal HSC donors and improving treat-
m e n t  o u t c o m e s  o f  U R D  H S C T  i n  K o r e a n  c h i l d r e n  w i t h  
malignant and non-malignant diseases.
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